The coronavirus (COVID-19) current therapy market consists of sales of drugs currently used for the treatment of COVID-19 infection. The market report includes single-drug therapeutics and combination drug therapeutics used in treating COVID-19 patients.
The global COVID-19 current therapy market is expected to grow from $10.83 billion in 2019 to $16.51 billion in 2020 at a compound annual growth rate (CAGR) of 52.5%. The growth is mainly attributed to the COVID-19 outbreak and the urgent need to treat the growing number of cases. With no effective therapeutics discovered so far, existing drugs such as Remdesivir, Hydroxychloroquine, Ritonavir, Lopinavir, Interferon Beta, among others are repurposed for the COVID-19 treatment. The market is then expected to stabilize and reach $27.27 billion in 2023 at a CAGR of 18.2%.
_Current_Therapy.png "Coronavirus (COVID-19) Current Therapy Market")
